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to electronic health care records (EHR) data. Methods: Using GNS Health care’s 
analytical platform (REFSTM), we built unbiased predictive models for progression 
to T2D, computationally exploring trillions of potential models, in Humedica data. 
Humedica’s data acquisition model aggregates de-identified EHR from providers 
across the continuum of care. Our study population consisted of 24,331 adults 
without history of prediabetes or T2D, from 2007-2012. Prediabetes was defined 
using World Health Organization criteria; incident T2D was identified using ICD-9 
codes. Accuracy of prediction models was assessed using an area under the curve 
(AUC) statistic. We validated resulting prediction models in an independent data-
set. Results: Our baseline model accurately predicted progression to T2D from 
normoglycemia (AUC = 0.76). We validated this model with an independent data-
set where the AUC increased to 0.78. When the model was extended to include 
time-varying covariates the AUC increased to 0.87. Our model of progression from 
normoglycemia to T2D consisted of established risk factors (blood glucose meas-
ures, hypertension, income, race, triglycerides, lipid disorders, and blood pressure), 
whereas predictors of progression to prediabetes included novel factors such as 
high-density lipoprotein, alanine aminotransferase, C-reactive protein, and core 
body temperature (AUC = 0.70). ConClusions: Using an extensive EHR data-
base, we built accurate prediction models of diabetes risk using a hypothesis-free, 
machine-learning Bayesian approach, and validated them with an independent 
dataset. In doing so, we identified novel factors representing emerging areas of 
diabetes research and potential new targets for clinical management. Our ability 
to make individual T2D risk predictions has valuable applications to personalized 
medicine and clinical trial recruitment.
Diabetes/enDocrine DisorDers – cost studies
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objeCtives: Estimating the budget impact of the introduction of vildagliptin as 
addition to insulin in the treatment of patients with type 2 diabetes mellitus with 
inadequate glycemic control (HbA1c> 7%) compared to the same group of patients 
treated with insulin monotherapy in Colombia, from third-party payer perspec-
tive. Methods: Markov model, which simulates the natural history of the disease, 
budget impact analysis (AIP) was made under the Colombian context for a five-year 
period using direct health costs associated with the natural history of the disease, 
including macrovascular and microvascular events and episode of hypoglycemia 
in a mobile cohort of patients, looking at prevalence, incidence and death. In the 
alternative scenarios, it will estimate reductions in insulin doses for the correspond-
ing arm vildagliptin in addition to insulin. Direct health care costs were taken from 
insurers and individual records of health benefits (RIPS) 2012. Results: With a 
disease prevalence and incidence rate of 0.04 & 0.00879 respectively in Colombia 
and assuming that 8.6% of patients require insulin according to the stage of the dis-
ease, the cumulative cost to 5 years of patients treated with insulin alone, would be 
COP $3,030,742,552,215(USD1.565.522,80), compared to COP $3,546,840,289,383(USD 
1.832.111,85) treated with insulin + Vildagliptin. Additionally, contemplating a reduc-
tion of approximately 27% in the dose of insulin, savings were generated under the 
use of vildagliptin in addition to insulin from the third year on total cost as well as 
reduction of cardiovascular and adverse events. Similarly, savings accumulated over 
the capitation payment unit of 0.000093% in 5 years, accompanied by lower mortal-
ity. ConClusions: The use of vildagliptin in addition to insulin will be significantly 
less expensive than using insulin monotherapy for patients with type 2 diabetes 
with inadequate glycemic control, in the Colombian health system context, along 
with better health care outcomes.
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(Phen/tPm er) in overweight anD obese Patients with comorbiD 
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objeCtives: This post-hoc analysis estimated the budget impact of PHEN/TPM ER 
7.5/46 mg in comparison with lifestyle modification (LM) alone in overweight and 
obese patients with comorbid prediabetes or T2DM. Methods: A 1-year budget 
impact model was developed from the health plan perspective evaluating pharmacy 
costs and comorbidity costs in overweight and obese patients with prediabetes or 
T2DM. Changes in body mass index (BMI) for PHEN/TPM ER 7.5/46 and LM were 
based on data from CONQUER, a phase 3, 56-week randomized trial (Gadde 2011). 
Comorbidity cost offsets for BMI reductions were calculated by multiplying the 
change in BMI by medical ($164) and pharmacy ($113) costs per unit of BMI (Wang 
2006). The rate of progression from prediabetes to T2DM was based on data from 
CONQUER. Literature-based estimates of the annual cost of treating prediabetes 
($535) and T2DM ($8069) were used to calculate comorbidity costs. The plan popula-
tion was assumed to be 1,000,000 patients and the market uptake of PHEN/TPM ER 
7.5/46 was assumed to be 1% at a weighted cost per capsule of $5.04. Results: In 
patients with prediabetes, BMI was reduced by 4.30kg/m2 for PHEN/TPM ER 7.5/46 
and 2.15kg/m2 for LM, translating to annual cost offsets of $1191 and $596, respec-
tively. The rate of progression from prediabetes to T2DM was 3.8% for PHEN/TPM ER 
and 9.6% for LM. In patients with T2DM, the BMI reduction was 3.69kg/m2 for PHEN/
TPM ER and 1.96kg/m2 for LM, translating to cost offsets of $1022 and $543, respec-
tively. The budget impact of adding PHEN/TPM ER 7.5/46 therapy was $0.01 per mem-
ber per month (PMPM) for prediabetes and $0.05 PMPM for T2DM. ConClusions: 
The budget impact of adding weight management therapy with PHEN/TPM ER in 
overweight or obese patients with prediabetes or T2DM is minimal and is offset by 
reduced comorbidity costs.
adult (ages 20-79) diabetes patients in Africa, ~1.5 times the prevalence in 2003. The 
continent-wide expenditure on diabetes in 2013 was ~$7.06 billion, compared to 
$2.72 billion in 2010, accounting for ~1% of global expenditures despite a prevalence 
burden of nearly 10% of global figures. The highest proportion of diabetes cases and 
spending were from northern Africa (40.4% of cases, 41.8% expenditures in 2013). 
However, eastern Africa (23.2% cases, 7.1% expenditures), western Africa (19.3% 
cases, 10.9% expenditures), and central Africa (8.6% cases, 4.2% expenditures), shoul-
der higher burdens of disease than their share of expenditures. In contrast, southern 
Africa (8.4% cases, 36% expenditures) has a lower percentage of overall patients, but 
spends significantly more than other regions. Data indicate that access to diabetes 
treatment is highly variable by region, and that disease management programs are 
infrequently available. Drug therapies are more broadly available, though costs can 
be a significant barrier to utilization. ConClusions: Rising disease prevalence will 
continue to stimulate demand for medical solutions in Africa. Northern and south-
ern Africa present a noteworthy market opportunity due to high disease prevalence 
and/or relatively high mean spending per patient. Affordable solutions that account 
for the variability in local market economics and implementation infrastructure are 
needed to support the growing diabetes burden in Africa.
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objeCtives: The aim of this study was to examine the geographic, age, gender 
and racial variations in the prevalence of diabetes in the U.S. Medicaid popula-
tion. Methods: This retrospective study analyzed a patient sample from the 
Medicaid fee-for-service (FFS) population in 2008 and 2009. Patients diagnosed with 
diabetes were identified using International Classification of Disease, 9thRevision, 
Clinical Modification (ICD-9-CM) diagnosis codes 250.x0 and 250.x2. Continuous 
Medicaid FFS enrollment was required during the 2-year study period. Patients 
were excluded if they had managed care enrollment in any month during the study 
period. Diabetes prevalence was analyzed by region, state, age, gender and race. The 
number and percentages of patients in each category were provided in the descrip-
tive analysis. Results: A total of 817,596 patients (16.66%) were diagnosed with 
diabetes among the Medicaid FFS population in 2008 through 2009. Patients over 
age 60 years had a higher prevalence (23.00%) than those age 40-59 (19.53%) or 0-39 
years (3.27%). Prevalence was also examined by race, with the highest prevalence 
found in Asian patients (22.17%), followed by Black (20.42%), Hispanic (16.89%), White 
(15.91%) and Native American (8.89%) patients. Prevalence of diabetes was much 
higher for female (18.36%) than for male patients (13.99%). U.S. states with the 
highest prevalence were Maryland (27.42%), Connecticut (26.73%), North Carolina 
(25.72%), Ohio (23.99%) and Indiana (23.51%). Prevalence trends were also strati-
fied by U.S. region: Midwest (18.12%), South (17.11%), Northeast (16.59%) and West 
(7.60%). ConClusions: The study results illustrate that elderly patients had a 
higher probability of being diagnosed with diabetes. Asian patients were more likely 
to be diagnosed with diabetes compared to other races. Female patients were at a 
higher risk for diabetes. Patients who resided in the Midwest U.S. region also had 
an increased likelihood of a diabetes diagnosis.
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objeCtives: Diabetes mellitus (DM) screening using hemoglobin A1c (HbA1c) is 
important to identify those at risk of cardiovascular disease. Little information is 
available on strategies for monitoring including frequency and timing of re-screen-
ing. We aimed to estimate the long-term between-person variation (“signal”) and 
short-term within-person variation (“noise”) of the HbA1c measures and evaluated 
the optical interval of re-checking HbA1c levels for DM screening. Methods: We 
conducted a retrospective cohort study including enrolled all people who consecu-
tively visited the St. Luke’s International Hospital Centre for Preventive Medicine 
(Tokyo, Japan) for a health check-up between 2005 and 2010. We measured the serum 
HbA1c annually. We estimated the ratio of “signal” to “noise” for HbA1c, adjusting for 
age, gender, using the random effects model. When the ratio of signal to noise was 
> = 1, we considered that screening interval appropriate. Results: A total of 34,662 
apparently healthy Japanese adults not taking diabetes medication at baseline had 
annual check-ups over 5 years. The mean age of the participants was 49 years old 
(SD: 12, range: 21 to 95) and 52% were male. Mean systolic blood pressure and BMI 
were 118 mmHg (SD: 17 mmHg) and 22.7 kg/m2 (SD: 3.7), respectively. Mean HbA1c 
level was 5.6% mg/dl (SD: 0.5%). Short-term within-person variations of HbA1c was 
0.10 (coefficient of variation, 6.1%) and long-term between-person variation were 
0.06 at 5 years and 0.13 at 7 years, respectively. The ratios of signal to noise were 
0.63 at 5 years and 1.2 at 7 years, respectively. ConClusions: Our findings suggest 
that the optimal interval of DM screening for healthy adults should be more than 
5 years using HbA1c.
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using electronic health recorDs anD ‘big Data’ analytics
Anderson J.P.1, Parikh J.R.1, Shenfeld D.K.1, Church B.W.1, Laramie J.M.1, Piper B.A.2, Willke R.J.2, 
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objeCtives: Type 2 diabetes (T2D) is strongly associated with morbidity and mor-
tality, and carries a heavy financial burden. An improved understanding of the 
factors that predict progression to prediabetes and T2D is warranted. Thus our 
objective was to identify these determinants, applying ‘big data’ analytic methods 
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patients. ConClusions: This BIA will be essential to support CONITEC’s decision 
about insulin analogues for T1DM patients in Brazil. Treatment costs still impressive, 
considering that analogues’ values reach 10 times the unit values of human insulins, 
fact that did not happen in other countries where they are already covered.
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objeCtives: The budget impact model (BIM) is recognized as a useful tool to help 
payers assess the economic value of new medicines approved for use. Although 
they are not considered as robust as cost effectiveness models, they do allow for 
short-term estimates of pharmacy impact and potential costs/offsets with the 
inclusion of the new medicine on formulary. Evolving IT platforms, such as the 
iPad, are offering new opportunities, but also changing end user expectations for 
these models. Albiglutide is an investigational, once weekly, Glucagon-Like Peptide-1 
Receptor Agonist (GLP-1RA) for the treatment of Type 2 Diabetes (T2D). We describe 
the development of an iPad application (app) derived from an excel-based BIM 
for use with US payer customers to inform access and reimbursement decisions 
for albiglutide. Methods: An excel-based BIM estimating the 1-5 year impact 
of including albiglutide on formulary compared to other available GLP-1RA’s was 
developed as per guidance from AMCP and following ISPOR good research prac-
tices. Given the increased use and demand for apps, we transformed the excel 
model into an app that would allow for modeling simulations to be run on an iPad 
adhering to these good practice guidelines. Results: The excel model was built 
according to the good practice guidelines and demonstrated the budget impact of 
introducing albiglutide for the treatment of T2D. The BIM was designed in a way 
to allow for successful conversion into a standalone app that utilized an improved 
user interface for interactive discussions around the value of albiglutide with US 
payers. ConClusions: The app version of the albiglutide BIM is a useful, comple-
mentary tool to the excel-based BIM. The app maintains its functionality according 
to ISPOR and AMCP recommendations.
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Public brazilian health system (sus)
Ferreira C.N., Rufino C.S., Manfrin D.F.
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objeCtives: This analysis aims to determine, in International Units (IU), the soma-
tropin volume waste of presentations with 4 IU and 12 IU compared to 16 IU and 
36 IU, when used for treatment of Turner Syndrome and for children treatment 
with disorders of growth due to deficiencies of growth hormone. Methods: The 
amount waste per month was analyzed, in IU, from the dosage indicated in the 
Project of Clinical Protocol Guideline (PCDT) for Hypopituitarism of the Brazilian 
Health Ministry and a comparative analysis was done between presentations of 
4 IU/ 12 IU (approved by Ministry) and of 16 IU/ 36 IU. Results: The average loss 
per treatment/month (Turner Syndrome and children with growth disorders) are 
18,36 IU, 12,08 IU, 0,38 IU and 2,01 IU presentations with 4IU,12IU, 16IU and 36IU 
respectively. ConClusions: Therefore, if the SUS adopt presentations of 16IU or 
36IU, that could be reduce the losses in an average of 97,5% and 87% respectively in 
month/patient, minimize the treatment cost, optimize doses number and achieve 
more patients. Moreover, it is more advantageous because they take up less space 
for storage and for transportation.
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objeCtives: To estimate the impact of the cost of diabetes mellitus (DM) in 
Brazil based on the ratio (“R”) of health care expenses of households with at least 
one person using medication for diabetes to those without diabetes medication 
use. Methods: We utilized data from the Family Budget Study (POF – Pesquisa de 
Orçamentos Familiares), a representative sample of 59.548 households investigated 
in 2008-2009 by the Brazilian Institute of Geography and Statistics (IBGE). The data 
were analyzed using Microsoft Excel and R (version 3.0.2). Households were catego-
rized based on the purchase (or no cost receipt) of diabetes medications by fam-
ily members. Expenses included those for hospitalization, medical consultations, 
health insurance, drugs and medical supplies. Analyses were conducted for Brazil, 
for regions and for those with and without health insurance coverage. Results are 
weighted so as to represent the Brazilian population. Results: Households with 
diabetes (6.2% of the total) more frequently (26.3% vs. 8.5%) had members > 60 years 
of age. Expenses increased with increasing household income. Overall, for Brazil, 
the ratio “R”, adjusted through regression analyses for the age and sex distribution 
of the family members, household income and regional location, was 1.81 (95%CI 
1.69-1.95), indicating that expenses were 81% greater in households where diabetes 
was present than in those without. The expenses with the purchase of medicines to 
treat DM increase with increasing income. ConClusions: Health care expenses 
are notably greater in Brazilian households having family members with diabetes.
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objeCtives: To estimate the budget impact of the use of saxagliptin/metformin 
XR fixed-dose combination compared to the current treatment of people with 
T2DM, in Venezuela. Methods: We used an MS Excel-based budget impact model 
assuming coverage of one million people in the health care system of Venezuela, 
with a 3-year time horizon. DM prevalence was obtained from published literature. 
Pharmaceutical expenses of oral antidiabetic agents (OADs) were analyzed exclud-
ing other medical costs. The cost of OADs was based upon list prices, expressed 
in Venezuelan Bolivars (VEF$) 2013 (exchange rate: 1 US-dollar = 6.30 VEF$). The 
market share of the different drugs was based upon QUALIDIAB Database, market 
studies and data provided by Bristol-Myers Squibb. A progressive increase of mar-
ket share was assumed for saxagliptin/metformin XR among all the OADs; 1.14%, 
2.65% and 3.0% for the 1st, 2nd and 3rd year, respectively. The budget impact is 
reported in terms of annual budget impact, per member per-month (PMPM) and 
per patient per month (PPPM). A Monte Carlo simulation (10,000 iterations) was 
done as part of the sensitivity analysis. Results: the net budget impact estimated 
for the introduction of saxagliptin/metformin XR combined was VEF$503,807 for 
the first year, VEF$1,183,333 for the second year and VEF$1,353,554 for the third 
year; the cumulative net budget impact was VEF$3,040,703. PMPM was VEF$0.04, 
VEF$0.10 and VEF$0.11 for the first, second and third year respectively. PPPM was 
VEF$1.67, VEF$4.0 and VEF$4.65 each year, respectively. The cumulative impact in 
the total annual budget for oral antidiabetic agents represented an increase of 2.36%. 
Monte Carlo simulation showed that cumulative budget impact varied from 1.32 to 
8.74%. ConClusions: incorporation of saxagliptin/metformin XR combination into 
the health care system of Venezuela, as a treatment option for people with T2DM, 
would have a minimal budgetary impact.
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buDget imPact analysis of utilizing canagliflozin (cana) for the 
treatment of tyPe 2 Diabetes mellitus (t2Dm) in an uniteD states 
health Plan
Vo L., Martin S.
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objeCtives: CANA, an SGLT2 inhibitor, is a recently approved oral antihyperglyce-
mic agent (AHA) for the treatment of adults with T2DM. As the prevalence and cost 
of T2DM continue to rise, payers seek treatment options to improve care and reduce 
cost. Budget impact analysis may help payers in the formulary decision-making 
process. To estimate the three-year budget impact of adding CANA to a hypothetical 
health plan formulary in place of other branded AHAs. Methods: The model was 
developed from the perspective of a US health plan with 1 million members. The 
prevalence of people diagnosed and treated with T2DM is based on US epidemiol-
ogy statistics. Drug costs were estimated using August 2013 wholesale acquisition 
costs. Publically available estimates of 2012 market shares of the branded AHAs and 
estimated 2013, 2014, and 2015 market shares of CANA for Years 1-3 (Year 1: 0.3%, 
Year 2: 1.8%, Year 3: 2.1%) were used. The base case analysis examined an increasing 
CANA market share with a proportional decrease in the market share of the other 
branded drugs. Results are presented as the difference in pharmacy budget, overall 
and per-member per-month (PMPM). Results: Prior to the introduction of CANA, 
the estimated pharmacy budget for branded non-insulin AHAs in this hypothetical 
plan was almost $48 MM/year. With CANA added to the formulary, the budget is 
forecasted to decrease by $71,902 at Year 1, $431,409 at Year 2, and $503,311 at Year 
3. The PMPM expenditures decrease from $4.00 when CANA was unavailable to $3.95 
at Year 3 of CANA uptake. ConClusions: The results show the positive budget 
impact of adding CANA to the formulary. As payers continually face rising health 
care costs, an AHA that can safely and effectively treat T2DM and lower pharmacy 
costs would be considered highly valuable.
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Laranjeira F., Mega T.P., Lima L.P.S., Salomon F.C.R., Petramale C.
Brazilian Ministry of Health, Brasília-DF, Brazil
objeCtives: Type 1 Diabetes Mellitus (T1DM) is an endocrine autoimmune disease 
with onset usually in childhood and which, being chronic, affects people of working 
age. It affects approximately 0.3% of the population and has high personal and social 
impact. The National Committee for Incorporation of Technologies in Health System 
(CONITEC) is responsible for recommending the inclusion or not of technologies in 
Brazilian public health system and has drawn up a budget impact analysis (BIA) of 
insulin analogues for the treatment of T1DM for help the decision making. Methods: 
A BIA of insulin analogues in SUS compared to human insulin (NPH and Regular) 
was performed. The analysis’ time horizon was 5 years, using a diabetes prevalence 
of 7.6% and 5% of T1DM between them (602,742), considering an annual growth rate 
of 0.8143% and a market share of 20%, 30%, 40%, 50% and 100%. The mean total 
insulin dose considered was 0.75IU/kg/day, with an average personal weight of 70kg, 
which means 52.5IU/day, 50% of each insulin type (basal and rapid). Unit purchase 
prices of insulins were obtained in the health system prices database and calcu-
lated the weighted average. For human insulins, were considered the values of last 
purchase of the Ministry of Health. Results: The budget impact of basal analogues 
would be R$202.8 million in the 1st year, considering 20% of target population, reach-
ing approximately R$1 billion in 100% of patients. For rapid analogues, the budget 
impact would be R$62.9 million in the 1st year, reaching R$324.9 million in 100% of 
